JPH09510468A - 皮膚疾患の治療のための及びその皮膚の消毒のためのゲル - Google Patents
皮膚疾患の治療のための及びその皮膚の消毒のためのゲルInfo
- Publication number
- JPH09510468A JPH09510468A JP7524380A JP52438095A JPH09510468A JP H09510468 A JPH09510468 A JP H09510468A JP 7524380 A JP7524380 A JP 7524380A JP 52438095 A JP52438095 A JP 52438095A JP H09510468 A JPH09510468 A JP H09510468A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- skin
- gel
- weight
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 40
- 208000017520 skin disease Diseases 0.000 title claims abstract description 15
- 238000004659 sterilization and disinfection Methods 0.000 title description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 109
- 239000000203 mixture Substances 0.000 claims abstract description 62
- 239000003349 gelling agent Substances 0.000 claims abstract description 30
- 230000000699 topical effect Effects 0.000 claims abstract description 13
- 210000003491 skin Anatomy 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 229920000896 Ethulose Polymers 0.000 claims description 20
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 claims description 17
- 229920000642 polymer Polymers 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 11
- 241000700584 Simplexvirus Species 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 210000000434 stratum corneum Anatomy 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 230000004888 barrier function Effects 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 229920003086 cellulose ether Polymers 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 244000078703 ectoparasite Species 0.000 claims description 3
- 229920006158 high molecular weight polymer Polymers 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 28
- 239000011159 matrix material Substances 0.000 abstract description 8
- 239000011505 plaster Substances 0.000 abstract description 7
- 239000000654 additive Substances 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000001704 evaporation Methods 0.000 abstract description 4
- 230000008020 evaporation Effects 0.000 abstract description 4
- 230000001681 protective effect Effects 0.000 abstract description 4
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 230000000996 additive effect Effects 0.000 abstract description 2
- 230000001112 coagulating effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 86
- 208000015181 infectious disease Diseases 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 13
- 239000000306 component Substances 0.000 description 12
- 229920002125 Sokalan® Polymers 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 206010040872 skin infection Diseases 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 244000045947 parasite Species 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 208000009889 Herpes Simplex Diseases 0.000 description 7
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000008733 trauma Effects 0.000 description 7
- 208000003322 Coinfection Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000001387 anti-histamine Effects 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 239000000739 antihistaminic agent Substances 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000645 desinfectant Substances 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 208000001688 Herpes Genitalis Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000004946 genital herpes Diseases 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000035874 Excoriation Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229940035674 anesthetics Drugs 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 206010019973 Herpes virus infection Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000006887 Ullmann reaction Methods 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- -1 for example Chemical compound 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000006128 skin development Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- HRANPRDGABOKNQ-ORGXEYTDSA-N (1r,3r,3as,3br,7ar,8as,8bs,8cs,10as)-1-acetyl-5-chloro-3-hydroxy-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate Chemical group C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1[C@H](O)C[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 HRANPRDGABOKNQ-ORGXEYTDSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-N Arsenic acid Chemical compound O[As](O)(O)=O DJHGAFSJWGLOIV-UHFFFAOYSA-N 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 206010073385 Blister rupture Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022535 Infectious Skin disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000509427 Sarcoptes scabiei Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000331598 Trombiculidae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940000488 arsenic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- ZBJVLWIYKOAYQH-UHFFFAOYSA-N naphthalen-2-yl 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=C(C=CC=C2)C2=C1 ZBJVLWIYKOAYQH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.液体及びその液体中に溶解された高分子量ポリマー・ゲル化剤を含んで成 る皮膚障害の治療のためのゲル形態の医薬組成物であって、その組成物が、その 組成物の全重量に基づき90重量%を上廻る低級アルカノール及びその組成物の全 重量に基づき10重量%未満の水を含んで成ることを特徴とするような医薬組成物 。 2.組成物中の水の濃度が、20−24℃のレンジ内の温度及び50〜100 %の相対 湿度における平衡含有量未満である、請求項1に記載の組成物。 3.ゲル化剤、アルカノール及び水だけから本質的に成る、請求項1又は2に 記載の組成物。 4.皮膚障害の治療におけるアルコールの効果を高める強化剤の有効量をさら に含み、そして他の医薬として活性な成分を実質的に含まない、請求項1又は2 に記載の組成物。 5.好ましくは、6〜9.5 のレンジ内のpHを与える量における塩基、例えば、 好ましくは、水酸化ナトリウム及びカリウム並びにトリエチルアミンから選ばれ た、無機アルカリ又は有機塩基を含む、請求項4に記載の組成物。 6.アルカノールが、エタノール、イソプロパノール及びそれらの混合物から 選ばれ、そして好ましくは、エタノールである、先の請求項のいずれか1項に記 載の組成物。 7.ゲル化剤が、セルロースの誘導体、好ましくは、セルロース・エーテル、 より好ましくは、エチル・ヒドロキシエチル・セルロースである、先の請求項の いずれか1項に記載の組成物。 8.水の濃度が、アルカノール・プラス水の重量に基づき、5%未満、好まし くは、3.3%未満である、先の請求項のいずれか1項 に記載の組成物。 9.水−及び水蒸気−不透過性容器内に収納された、先の請求項のいずれか1 項に記載の組成物。 10.ウイルスに感染した皮膚の治療のための、全組成物重量に基づき、少なく とも90重量%の低級アルカノール及び10%未満の水、を含む組成物の製造におけ る、ポリマー・ゲル化剤と低級アルカノールの組合せの使用。 11.ウイルス感染が、単純ヘルペス・ウイルスからのものである、請求項10に 記載の使用。 12.外部寄生虫に感染した皮膚の治療のための、全組成物及びゲル化剤に基づ き、少なくとも90重量%の低級アルカノール及び5重量%未満の水を含むゲル形 成組成物の製造における、ポリマー・ゲル化剤と低級アルカノールの組合せの使 用。 13.請求項2〜9のいずれか1項に規定するさらなる特徴を含む、請求項10〜 12のいずれか1項に記載の使用。 14.表在局所的適用による、皮膚障害の治療のための組成物の製造におけるエ チルヒドロキシエチル・セルロースの使用。 15.少なくとも90重量%の低級アルカノール及び有効ゲル化量のエチルヒドロ キシエチル・セルロースを含む組成物。 16.治療薬(Medicament)としての使用のための、請求項15に記載の組成物。 17.ポリマー・ゲル化剤、組成物の全重量に基づき、90重量%を上廻る低級ア ルカノール及び10重量%未満の水を含んで成るゲル形成医薬組成物の感染皮膚領 域への表在局所的適用による感染した皮膚の治療方法。 18.治療が、角質層よりも深い皮膚の層に影響を及ぼすために有効である、請 求項17に記載の方法。 19.組成物が、少なくとも2時間、好ましくは、少なくとも4時間の期間にわ たり、障害を罹患した領域に接して残って、ポリマーの粘着性バリア・フィルム を形成する、請求項17又は18に記載の方法。 20.皮膚への表在局所的適用による角質層下の皮膚の層の障害の治療方法にお ける使用のための組成物の製造における医薬として活性な成分としての低級アル カノールの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK32594 | 1994-03-21 | ||
DK0325/94 | 1994-03-21 | ||
PCT/EP1995/001025 WO1995025544A1 (en) | 1994-03-21 | 1995-03-20 | Gel for treatment of skin diseases and for disinfection of the skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09510468A true JPH09510468A (ja) | 1997-10-21 |
JP3560977B2 JP3560977B2 (ja) | 2004-09-02 |
Family
ID=8092278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52438095A Expired - Fee Related JP3560977B2 (ja) | 1994-03-21 | 1995-03-20 | 皮膚疾患の治療のための及びその皮膚の消毒のためのゲル |
Country Status (26)
Country | Link |
---|---|
US (4) | US5981605A (ja) |
EP (1) | EP0751789B1 (ja) |
JP (1) | JP3560977B2 (ja) |
KR (1) | KR100396278B1 (ja) |
CN (1) | CN1146725A (ja) |
AT (1) | ATE208212T1 (ja) |
AU (1) | AU701872B2 (ja) |
BR (1) | BR9507164A (ja) |
CA (1) | CA2186045A1 (ja) |
CZ (2) | CZ286758B6 (ja) |
DE (1) | DE69523745T2 (ja) |
DK (1) | DK0751789T3 (ja) |
EE (1) | EE03293B1 (ja) |
ES (1) | ES2168111T3 (ja) |
FI (1) | FI963696A (ja) |
HU (1) | HUP9774641A2 (ja) |
LV (1) | LV12951B (ja) |
MX (1) | MX9604208A (ja) |
NO (1) | NO314126B1 (ja) |
NZ (1) | NZ283135A (ja) |
PL (1) | PL179918B1 (ja) |
PT (1) | PT751789E (ja) |
RU (1) | RU2142273C1 (ja) |
SK (1) | SK281575B6 (ja) |
UA (1) | UA41989C2 (ja) |
WO (1) | WO1995025544A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008260888A (ja) * | 2007-04-13 | 2008-10-30 | Kao Corp | ゲル化剤 |
JP2010511723A (ja) * | 2006-12-04 | 2010-04-15 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 局所医薬組成物 |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995025544A1 (en) * | 1994-03-21 | 1995-09-28 | John Brown Thomsen | Gel for treatment of skin diseases and for disinfection of the skin |
US6416760B2 (en) * | 1995-01-26 | 2002-07-09 | Societe L'oreal | Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin |
FR2732221B1 (fr) * | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
DE19624508A1 (de) * | 1996-06-19 | 1998-01-08 | Guetter Hans Peter Dr | Verwendung von C¶3¶-C¶4¶-Alkoholen zur Behandlung von Herpeserkrankungen |
AU729078B2 (en) * | 1996-06-24 | 2001-01-25 | Bio-Safe Enterprises, Inc. | Antibacterial composition |
US7767216B2 (en) * | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US8173709B2 (en) * | 1999-09-22 | 2012-05-08 | Quadex Pharmaceuticals, Llc | Anti-infective methods for treating pathogen-induced disordered tissues |
US6759434B2 (en) | 1999-09-22 | 2004-07-06 | B. Ron Johnson | Anti-infective compositions, methods and systems for treating disordered tissue |
CN1452629A (zh) * | 2000-05-31 | 2003-10-29 | 科学技术振兴事业团 | 含有人参皂甙Rb1的皮肤组织再生促进剂 |
AUPR028000A0 (en) * | 2000-09-21 | 2000-10-12 | Hair Advisory Centre Pty. Ltd. | Ectoparasite formulation |
US6581775B1 (en) * | 2001-08-10 | 2003-06-24 | Garo Hagopian | Method of external genital cleansing and prophylactic kit |
CA2421026C (en) * | 2001-10-16 | 2005-02-15 | Avanir Pharmaceuticals | Viral inhibition by n-docosanol |
US20050042240A1 (en) * | 2002-01-28 | 2005-02-24 | Utterberg David S. | High viscosity antibacterials |
DE10219597A1 (de) * | 2002-05-02 | 2003-11-20 | Wella Ag | Wasserfreie Haarstylinggele |
AU2003242235A1 (en) * | 2002-06-18 | 2003-12-31 | Pola Chemical Industries Inc. | Antifungal medicinal composition |
US20040191286A1 (en) * | 2003-03-24 | 2004-09-30 | Bijan Safai | Head lice medication and treatment |
GB0318160D0 (en) * | 2003-08-02 | 2003-09-03 | Ssl Int Plc | Parasiticidal composition |
US8741332B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
US20070196453A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs |
US8741333B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
US8907153B2 (en) | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
US20060024372A1 (en) * | 2004-07-29 | 2006-02-02 | Utterberg David S | High viscosity antibacterials |
US7268165B2 (en) * | 2004-08-20 | 2007-09-11 | Steris Inc. | Enhanced activity alcohol-based antimicrobial compositions |
US20070116749A1 (en) * | 2005-11-21 | 2007-05-24 | Grossman Leonard D | Method for treatment of cellulitis |
DE102005059742A1 (de) | 2005-12-13 | 2007-06-14 | Beiersdorf Ag | Transparentes Sonnenschutzmittel |
ES2577390T3 (es) | 2006-07-21 | 2016-07-14 | Biodelivery Sciences International, Inc. | Dispositivos de administración transmucosa con mayor captación |
EP2059125B1 (en) | 2006-10-23 | 2013-08-14 | Ecolab Inc. | Virucidal composition |
WO2008137747A1 (en) | 2007-05-02 | 2008-11-13 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US20100247564A1 (en) * | 2007-05-24 | 2010-09-30 | David Yue-Wei Lee | Methods and compositions for the use of sargassum fusiforme for the inhibition of hiv-1 infection |
DE102008028993A1 (de) * | 2007-06-29 | 2009-01-08 | Bode Chemie Gmbh & Co. Kg | Verwendung eines alkoholischen Desinfektionsmittels zur Schnelldesinfektion |
EA013233B1 (ru) * | 2008-06-12 | 2010-04-30 | Иностранное Частное Унитарное Производственно-Торговое Предприятие "Инкраслав" Фирмы "Вера, О.О.О. Прешов" | Антисептическая композиция для дезинфекции кожных покровов, способ ее приготовления и полупродукт для ее приготовления |
US20100158821A1 (en) * | 2008-12-22 | 2010-06-24 | Eastman Chemical Company | Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products |
US8106111B2 (en) | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
EP2512231B1 (en) * | 2009-12-16 | 2016-12-07 | Ecolab Inc. | Composition in form of a gel for the virucidal disinfection of mammalian skin |
US10383894B2 (en) * | 2010-03-17 | 2019-08-20 | Lutran Industries, Inc. | Human medicinal treatment using salt of peroxymonosulfuric acid |
GB201010256D0 (en) * | 2010-06-18 | 2010-07-21 | Reckitt Benckiser Inc | Germicidal topical compositions |
FR2976808B1 (fr) * | 2011-06-22 | 2013-06-28 | Urgo Lab | Composition filmogene et son utilisation pour le traitement de l'herpes |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
US9125911B2 (en) | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
US10071233B2 (en) * | 2015-05-22 | 2018-09-11 | L'oreal | Point applicator for treating skin conditions |
US10334853B2 (en) * | 2016-03-29 | 2019-07-02 | Larada Sciences | Compositions and methods for treating ectoparasite infestation |
EP4048237B1 (en) * | 2019-10-25 | 2024-02-28 | Mucocort AB | Treatment of inflammatory condition in mucous membrane or skin with low amounts of propylene glycol |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2054989A (en) * | 1933-12-30 | 1936-09-22 | Us Ind Alcohol Co | Compositions for application to the human skin |
DE1000367B (de) | 1952-11-17 | 1957-01-10 | Mo Och Domsjoe Ab | Verfahren zur Herstellung von in Wasser und/oder Alkali loeslichen Celluloseaethern |
US3016328A (en) * | 1961-01-03 | 1962-01-09 | Ethicon Inc | Dialdehyde alcoholic sporicidal composition |
US4019521A (en) * | 1973-06-06 | 1977-04-26 | Philip Morris Incorporated | Smokable material and method for preparing same |
US3876771A (en) * | 1973-09-04 | 1975-04-08 | Hallister Inc | Skin protective gel containing polyvinyl methylether or monoisopropyl ester of polyvinyl methylether maleic acid |
GB1582744A (en) * | 1976-06-04 | 1981-01-14 | Gruenenthal Gmbh | 7h-thiazolo (and 1,3,4-thiadiazolo-)(3,2-a) pyrimidin-7-one-5-carboxylic acids derivatives and medicaments therof |
SE418686B (sv) * | 1978-03-31 | 1981-06-22 | Landstingens Inkopscentral | Vattenbaserad salva for huddesinfektion innehallande alkohol som desinfektionsmedel |
GB1593097A (en) * | 1978-05-26 | 1981-07-15 | Fisons Ltd | Pharmaceutical compositions containing a bischromone |
US4256872A (en) * | 1978-09-26 | 1981-03-17 | Occidental Research Corporation | Process for preparing layered organophosphorus inorganic polymers |
US4247547A (en) * | 1979-03-19 | 1981-01-27 | Johnson & Johnson | Tretinoin in a gel vehicle for acne treatment |
US4590214A (en) * | 1980-04-14 | 1986-05-20 | Sepreh, Inc. | Method of treatment for herpes |
JPS5855411A (ja) * | 1981-09-28 | 1983-04-01 | Nitto Electric Ind Co Ltd | 基剤組成物および外用医薬組成物 |
US4431633A (en) * | 1982-04-27 | 1984-02-14 | Merck & Co., Inc. | Influenza vaccine |
DE3430709A1 (de) * | 1984-08-21 | 1986-03-06 | Krüger GmbH & Co KG, 5060 Bergisch Gladbach | Viruzides mittel |
US5288486A (en) * | 1985-10-28 | 1994-02-22 | Calgon Corporation | Alcohol-based antimicrobial compositions |
US4671955A (en) * | 1986-03-31 | 1987-06-09 | Victor Palinczar | Waterproof sunscreen compositions |
FR2613621B1 (fr) * | 1987-04-10 | 1990-06-29 | Roussel Uclaf | Butyl hydroxyanisoles pour utilisation dans le traitement prophylactique des maladies a retro-virus comme agents modificateurs de l'infectivite des retro-virus et produits anti-infectants |
US5098717A (en) * | 1987-12-09 | 1992-03-24 | Thames Pharmacal Co., Inc. | Method of treatment for pruritus |
US5013545A (en) * | 1987-12-09 | 1991-05-07 | Thames Pharmacal Co., Inc. | Aqueous gels containing topical medicaments |
CA1337329C (en) * | 1989-01-31 | 1995-10-17 | Paul L. Simmons | Biodegradable disinfectant |
US4923875A (en) * | 1989-07-10 | 1990-05-08 | Baker Cummins Pharmaceuticals, Inc. | Method for treatment of mast cell-mediated dermatologic disorders |
US5331012A (en) * | 1990-07-30 | 1994-07-19 | Riddick Kenneth B | Topical pharmaceutical preparation for fever blisters and other viral infections and method of use |
SE466134B (sv) * | 1990-11-22 | 1992-01-07 | Kabi Pharmacia Ab | Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner |
ATE152356T1 (de) * | 1991-06-20 | 1997-05-15 | Viro Tex Corp | Topisches präparat zur besseren heilung von herpesverletzungen |
US5376366A (en) | 1992-11-12 | 1994-12-27 | John Petchul | Composition and process for forming isopropyl alcohol gel with water-soluble vinyl polymer neutralizing agent |
WO1995025544A1 (en) * | 1994-03-21 | 1995-09-28 | John Brown Thomsen | Gel for treatment of skin diseases and for disinfection of the skin |
US5665751A (en) * | 1995-06-07 | 1997-09-09 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
-
1995
- 1995-03-20 WO PCT/EP1995/001025 patent/WO1995025544A1/en active IP Right Grant
- 1995-03-20 DK DK95928856T patent/DK0751789T3/da active
- 1995-03-20 EP EP95928856A patent/EP0751789B1/en not_active Expired - Lifetime
- 1995-03-20 MX MX9604208A patent/MX9604208A/es not_active IP Right Cessation
- 1995-03-20 AT AT95928856T patent/ATE208212T1/de not_active IP Right Cessation
- 1995-03-20 PL PL95316651A patent/PL179918B1/pl not_active IP Right Cessation
- 1995-03-20 ES ES95928856T patent/ES2168111T3/es not_active Expired - Lifetime
- 1995-03-20 PT PT95928856T patent/PT751789E/pt unknown
- 1995-03-20 AU AU21099/95A patent/AU701872B2/en not_active Ceased
- 1995-03-20 HU HU9602583A patent/HUP9774641A2/hu unknown
- 1995-03-20 DE DE69523745T patent/DE69523745T2/de not_active Expired - Fee Related
- 1995-03-20 KR KR1019960705197A patent/KR100396278B1/ko not_active IP Right Cessation
- 1995-03-20 CZ CZ19962723A patent/CZ286758B6/cs not_active IP Right Cessation
- 1995-03-20 SK SK1194-96A patent/SK281575B6/sk unknown
- 1995-03-20 JP JP52438095A patent/JP3560977B2/ja not_active Expired - Fee Related
- 1995-03-20 UA UA96103958A patent/UA41989C2/uk unknown
- 1995-03-20 US US08/714,162 patent/US5981605A/en not_active Expired - Fee Related
- 1995-03-20 CN CN95192710A patent/CN1146725A/zh active Pending
- 1995-03-20 EE EE9600195A patent/EE03293B1/xx not_active IP Right Cessation
- 1995-03-20 BR BR9507164A patent/BR9507164A/pt not_active IP Right Cessation
- 1995-03-20 NZ NZ28313595A patent/NZ283135A/xx unknown
- 1995-03-20 CA CA002186045A patent/CA2186045A1/en not_active Abandoned
- 1995-03-20 RU RU96120210A patent/RU2142273C1/ru not_active IP Right Cessation
-
1996
- 1996-09-18 FI FI963696A patent/FI963696A/fi not_active IP Right Cessation
- 1996-09-20 NO NO19963971A patent/NO314126B1/no unknown
-
1999
- 1999-10-13 US US09/416,940 patent/US6342537B1/en not_active Expired - Fee Related
- 1999-11-05 CZ CZ19993933A patent/CZ288150B6/cs not_active IP Right Cessation
-
2001
- 2001-12-12 US US10/012,303 patent/US20020086905A1/en not_active Abandoned
-
2002
- 2002-11-04 LV LVP-02-191A patent/LV12951B/en unknown
-
2003
- 2003-08-19 US US10/642,650 patent/US20040054015A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010511723A (ja) * | 2006-12-04 | 2010-04-15 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 局所医薬組成物 |
JP2008260888A (ja) * | 2007-04-13 | 2008-10-30 | Kao Corp | ゲル化剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3560977B2 (ja) | 皮膚疾患の治療のための及びその皮膚の消毒のためのゲル | |
JP7054212B2 (ja) | 有効な創傷ケア処置としての新規高速付着薄膜形成組成物 | |
JP5740393B2 (ja) | 皮膚および爪の真菌感染症の局所治療に適した組成物 | |
US20020077315A1 (en) | Bioadhesive antibacterial wound healing composition | |
JP2012523449A (ja) | スルファジアジン銀およびキトサンを使用して製造された薬用クリーム剤ならびにそれを製造する方法 | |
JP3899267B2 (ja) | 皮膚、粘膜、器官または組織の疾患を治療するためのトシルクロルアミドの使用 | |
RU2184538C2 (ru) | Применение дихлорбензилового спирта для получения лекарственного средства для местного лечения воспаления и лекарственное средство, содержащее дихлорбензиловый спирт | |
JPH11511180A (ja) | 化粧品のための物理的殺菌用ゲル | |
RU2481835C2 (ru) | Ранозаживляющее средство для местного применения | |
US3026247A (en) | Pharmaceutical preparation | |
JPS59196825A (ja) | 粘膜保護剤 | |
RU2181583C1 (ru) | Средство для лечения и профилактики болезней органов челюстно-лицевой области | |
RU2173155C1 (ru) | Ранозаживляющий, противовоспалительный и противоинфекционный лекарственный препарат | |
RU2682454C1 (ru) | Мазь для лечения термических ожогов и способ их лечения | |
RU2360666C2 (ru) | Комплексный антисептик для лечения животных с гнойными, гнойно-некротическими и гнойно-гнилостными поражениями тканей | |
AU2001242100B2 (en) | Pharmaceutical gel composition | |
ITPD960238A1 (it) | Composizioni farmaceutiche per uso vaginale e rettale comprendenti acido ialuronico o suoi derivati da soli o in associazione con agenti |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031201 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040302 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040427 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040527 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |